Best practices guideline: T6oxicologic histopathology

被引：255

作者：

Crissman, JW

Goodman, DG

Hildebrandt, PK

Maronpot, RR

Prater, DA

Riley, JH

Seaman, WJ

Thake, DC

机构：

[1] Pfizer Inc, Kalamazoo, MI 49001 USA

[2] Dow Corning Corp, Hlth & Environm Sci, Midland, MI 48686 USA

[3] Covance Labs Inc, Vienna, VA 22182 USA

[4] Pathco Inc, Frederick, MD 21702 USA

[5] NIEHS, Lab Expt Pathol, Res Triangle Pk, NC 27709 USA

[6] US FDA, Ctr Vet Med, Rockville, MD 20855 USA

[7] Estuary Pharmaceut, Cambridge, MA 02139 USA

来源：

TOXICOLOGIC PATHOLOGY | 2004年 / 32卷 / 01期

关键词：

toxicology; histopathology; methods; best practice; pathology; microscopy; guideline;

D O I：

10.1080/01926230490268756

中图分类号：

R36 [病理学];

学科分类号：

100104 [病理学与病理生理学];

摘要：

This best practices guideline for toxicologic histopathology identifies the process elements necessary for high-quality histopathologic evaluation of toxicology studies. It is not intended to address the science of toxicologic histopathology, only procedural considerations that are necessary to produce valid study results. The qualifications, training, experience and effectiveness of the study pathologist, in the broadest context, clearly represent the most essential factors in determining the quality of the pathology evaluation and the interpretation.

引用

页码：126 / 131

页数：6

共 20 条

[1]

BANCROFT JD, 1994, MAN HIST TECHN THEIR

[2]

BLACK HE, 1991, TOXICOL PATHOL, V19, P290

[3]

Study pathologist perspective of pathology peer review [J].